SCHEMBL375904

SCHEMBL375904

C1=C2CC2CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15924379 0.72
SCHEMBL29465180 0.70
SCHEMBL30061271 0.70
Bromide SCHEMBL3714719 0.69
SCHEMBL25389706 0.69
SCHEMBL18339589 0.67
SCHEMBL30657174 0.67
SCHEMBL7407751 0.61
SCHEMBL13512592 0.48
SCHEMBL10330777 0.48

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0008813-B1 PROCESSES FOR THE PREPARATION OF 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1982-12-01 EP claimed
CN-114874209-B Oxadiazole transient receptor potential channel inhibitors 豪夫迈·罗氏有限公司 2024-08-06 CN disclosed
WO-2024140637-A1 OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-07-04 WO disclosed
US-20230391766-A1 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER GENENTECH, INC. (US) 2023-12-07 US disclosed
WO-2023220237-A1 BENZOTHIAZOLE COMPOUNDS AS VHL LIGANDS GENENTECH, INC. (US) 2023-11-16 WO disclosed
EP-4244218-A1 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER Genentech, Inc. (US) 2023-09-20 EP disclosed
US-20230271944-A1 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA GENENTECH, INC. (US) 2023-08-31 US disclosed
WO-2022103411-A1 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER GENENTECH, INC. (US) 2022-05-19 WO disclosed
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof GENENTECH, INC. (US) 2022-02-08 US disclosed
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-10-07 US disclosed
WO-2018162607-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-09-13 WO disclosed
US-9782498-B2 Selective delivery molecules and methods of use AVELAS BIOSCIENCES, INC. (US) 2017-10-10 US disclosed
WO-2016131380-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO.,LTD. (CN) 2016-08-25 WO disclosed
US-20150359908-A1 SELECTIVE DELIVERY MOLECULES AND METHODS OF USE AVELAS ACQUISITION CORPORATION 2015-12-17 US disclosed
EP-2951210-A1 SELECTIVE DELIVERY MOLECULES AND METHODS OF USE Avelas Biosciences, Inc. (US) 2015-12-09 EP disclosed
WO-2014120974-A1 SELECTIVE DELIVERY MOLECULES AND METHODS OF USE AVELAS BIOSCIENCES, INC. (US) 2014-08-07 WO disclosed
EP-2079743-B1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD (GB) 2012-01-25 EP disclosed
US-20100216802-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. (GB) 2010-08-26 US disclosed
EP-2079743-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER Chroma Therapeutics Limited (GB) 2009-07-22 EP disclosed
WO-2008050096-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. (GB) 2008-05-02 WO disclosed